# Wenxian Wang
**Type:** Researchers
**Canonical URL:** https://scholariq.org/researchers/wenxian-wang/
## Facts
| Field | Value |
| --- | --- |
| Citations | 3,268 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 32 |
| i10-index | 100 |
| Last Known Institution | Cancer Hospital of Chinese Academy of Medical Sciences |
| OpenAlex ID | https://openalex.org/A5100600919 |
| ORCID iD | 0000-0002-3047-4149 |
| Works | 234 |
## Researcher papers
- [Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC](https://scholariq.org/papers/identification-of-deleterious-i-notch-i-mutation-as-novel-predictor-to/)
- [Allele Frequency–Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors](https://scholariq.org/papers/allele-frequency-adjusted-blood-based-tumor-mutational-burden-as-a-predictor-of/)
- [A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR‐TKI resistance](https://scholariq.org/papers/a-comparison-of-ddpcr-and-arms-for-detecting-egfr-t790m-status-in-ctdna-from/)
- [TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma](https://scholariq.org/papers/tp53-mutation-as-potential-negative-predictor-for-response-of-anti-ctla-4/)
- [Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study](https://scholariq.org/papers/genomic-alterations-and-clinical-outcomes-in-patients-with-lung-adenocarcinoma/)
- [TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib](https://scholariq.org/papers/tp53-mutations-predict-for-poor-survival-in-alk-rearrangement-lung/)
- [Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial](https://scholariq.org/papers/efficacy-and-safety-of-pyrotinib-in-advanced-lung-adenocarcinoma-with-her2/)
- [Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering](https://scholariq.org/papers/discovery-of-az0108-an-orally-bioavailable-phthalazinone-parp-inhibitor-that/)
- [Discovery of a 5H-Benzo\[4,5\]cyclohepta\[1,2-b\]pyridin-5-one (MK-2461) Inhibitor of c-Met Kinase for the Treatment of Cancer](https://scholariq.org/papers/discovery-of-a-5-i-h-i-benzo-4-5-cyclohepta-1-2-i-b-i-pyridin-5-one-mk-2461/)
- [Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial](https://scholariq.org/papers/pyrotinib-in-patients-with-her2-amplified-advanced-non-small-cell-lung-cancer-a/)
## Researcher topics
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
## Researcher university
- [Cancer Hospital of Chinese Academy of Medical Sciences](https://scholariq.org/institutions/cancer-hospital-of-chinese-academy-of-medical-sciences/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.